HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

By Falo Catalina   Moreno Abelardo   Varela Mar   Lloveras Belen   Figueras Agnès   Escobedo Agustín  

Journal of Cancer Research and Clinical Oncology, Vol. 133, Iss. 7, 2007-07 ,pp. : 423-429

Springer Publishing Company

Access to resources Recommend Favorite

Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study

By Schaapveld Michael   Vries Elisabeth   Graaf Winette   Otter Renée   Willemse Pax  

Journal of Cancer Research and Clinical Oncology, Vol. 130, Iss. 10, 2004-10 ,pp. : 581-590

Springer Publishing Company

Access to resources Recommend Favorite

Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer

By Qi Meng   Li Jin   Xie Yun   Lu Ai   Lin Ben   Ouyang Tao  

Breast Cancer Research and Treatment, Vol. 123, Iss. 1, 2010-08 ,pp. : 197-202

Springer Publishing Company

Access to resources Recommend Favorite

Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression

By Rocca Andrea   Viale Giuseppe   Gelber Richard   Bottiglieri Luca   Gelber Shari   Pruneri Giancarlo   Ghisini Raffaella   Balduzzi Alessandra   Pietri Elisabetta   D’Alessandro Claudia   Goldhirsch Aron   Colleoni Marco  

Cancer Chemotherapy and Pharmacology, Vol. 61, Iss. 6, 2008-05 ,pp. : 965-971

Springer Publishing Company

Access to resources Recommend Favorite

Changes of biological features in breast cancer cells determined by primary chemotherapy

By Frassoldati A.  

Breast Cancer Research and Treatment, Vol. 44, Iss. 3, 1997-07 ,pp. : 185-192

Springer Publishing Company

Access to resources Recommend Favorite